The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.

The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.

The oncolytic adenovirus Delta24-RGD represents a new promising therapeutic agent for patients with a malignant glioma and is currently under investigation in clinical phase I/II trials. Earlier preclinical studies showed that Delta24-RGD is able to effectively lyse tumor cells, yielding promising r...

Full description

Bibliographic Details
Main Authors: Anne Kleijn, Jenneke Kloezeman, Elike Treffers-Westerlaken, Giulia Fulci, Sieger Leenstra, Clemens Dirven, Reno Debets, Martine Lamfers
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4035348?pdf=render

Internet

http://europepmc.org/articles/PMC4035348?pdf=render

Similar Items